# ADMA Biologics, Inc. (ADMA): MoatMap facts

As of 24 Oct 2026. Research data, not investment advice.

As of 24 Oct 2026, MoatMap's StockRank for ADMA Biologics, Inc. (ADMA) is 77/100, ranked against 24,000+ stocks in 35 markets (Quality 82, Value 52, Momentum 39, each scored against its sector).

- StockRank: 77/100, a percentile across 24,000+ stocks in 35 markets (100 is best).
- Quality 82, Value 52, Momentum 39: each a 0-100 percentile within Healthcare.
- Position: #6,206 overall, #674 in Healthcare.
- Listing: United States, NGM; Healthcare / Biotechnology.
- Last close: 11.065 USD on 26 Oct 2026.
- Insider filings, last 180 days: directors bought USD 251K.
- Buybacks, last 180 days: the company bought back USD 30.3M on 2 days.

Source: https://moatmap.ai/stock/ADMA
How the scores work: https://moatmap.ai/methodology
Does StockRank work? The public record: https://moatmap.ai/decile-tracker